Clinical Trial Update: Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC [Phase 3]

View source ↗

Summary

Phase 3 trial investigating BCD-100 (anti-PD-1) with platinum chemotherapy as first-line therapy for advanced non-squamous non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BCD-100 (unclear)

Snippet

Sponsor: Biocad | Conditions: Non-Squamous Non-Small Cell Neoplasm of Lung | Phase 3 | Status: UNKNOWN